MY143795A
(en )
2011-07-15
Tetrahydropyridoindole derivatives
TW200605870A
(en )
2006-02-16
Topical methadone compositions and methods for using the same
WO2004021968A3
(en )
2004-05-27
Solution for ungual application
WO2005041925A3
(en )
2005-09-29
Compositions and dosage forms for enhanced absorption
WO2004030611A3
(en )
2004-06-17
Non-nucleoside reverse transcriptase inhibitors
AU2003274681A1
(en )
2004-02-23
Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
MY144992A
(en )
2011-12-15
Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MXPA04004837A
(es )
2004-08-02
Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0
(en )
2004-08-31
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006096434A3
(en )
2007-03-29
Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2008028965A3
(en )
2008-06-19
Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2008148074A3
(en )
2009-03-19
Inhibitors of mtor and methods of treatment using same
TNSN07203A1
(en )
2008-11-21
Pharmaceutical compositions for the treatment of cellulite
PL1654253T3
(pl )
2007-05-31
Podstawione pochodne 3-pirolidynoindolu
WO2009061431A3
(en )
2009-07-23
Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2008042480A3
(en )
2008-08-14
Epoxide inhibitors of cysteine proteases
PL1962815T3
(pl )
2011-02-28
Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
MXPA03010054A
(es )
2004-04-02
Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
WO2007062093A3
(en )
2008-10-23
Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2009088673A3
(en )
2009-09-11
Pharmaceutical composition
EP1503748A4
(en )
2009-10-21
DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
WO2003068157A3
(en )
2004-03-04
Kinase inhibitors and methods of use thereof
WO2003090688A3
(en )
2007-11-15
Enhancement of human epidermal melanogenesis
CA2494473A1
(en )
2005-04-25
Stabilized protein compositions for topical administration and methods of making same
PT1646378E
(pt )
2008-12-17
Composições farmacêuticas que compreendem ácido ascórbico para o tratamento de superinfecções fúngicas e recorrências fúngicas